top of page
Recent Posts

Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer

  • OPACC
  • Jul 14, 2015
  • 1 min read

US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ), today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.

Comments


Archive
Search By Tags
Rama logo.png
cgcg logo.jpg

524 Bayfield Street North
P.O. Box 20005
Barrie, ON L4M 5E9
Canada

info@opacc.org

705-828-7965

  • Wix Facebook page
  • Wix Twitter page
  • Instagram Social Icon
  • YouTube Social  Icon
bottom of page